Atlas Trials

A New Prognostic Stratification-based Safety and Efficacy Study of Ruxolitinib in Myelofibrosis

Clinical trial NCT05447260 · UNKNOWN

Trial details

NCT number
NCT05447260
Sponsor
Qilu Hospital of Shandong University
Status
UNKNOWN
Phase
Phase 4
Study type
INTERVENTIONAL
Myelofibrosis
Start date
2022-06-10
Primary completion
2022-12-10
Enrollment
87

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.